Exhibit 25

 

 

 

Grown Rogue Reports Fourth Quarter and Annual 2024 Results

 

Medford, Oregon, March 31, 2025 – Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a craft cannabis company born from the amazing terroir of Oregon’s Rogue Valley, is pleased to report its fourth quarter and full year results ended December 31, 2024. The Company changed its fiscal year-end from October to December during 2024, affecting year-over-year comparison periods, including making year-over-year quarterly comparisons less relevant. All financial information is provided in U.S. dollars unless otherwise indicated.

 

2024 Operational and Financial Highlights:

 

Revenue of $27.0M compared to $23.4M in the year ended October 31, 2023, an increase of 16%

 

Adjusted EBITDA of $9.7M compared to $7.6M in the year ended October 31, 2023, an increase of 27%

 

Adjusted EBITDA margin of 35.8% compared to 32.7% in the year ended October 31, 2023

 

Grown Rogue Received Licensing Approval in New Jersey and Closed Option 1 to Acquire 44% of ABCO Garden State, LLC (“ABCO”), with agreements in place to own up to 70%, pending regulatory approval

 

Commenced sales of Grown Rogue flower and pre-rolls in New Jersey in December and, as of mid-March, are selling into approximately half of the 205 dispensaries in the state

 

Increased ownership of Michigan operations from 60% to 80%

 

Convertible lenders voluntarily converted $3.1M of outstanding convertible debentures not due until 2027

 

Announced the termination of the advisory agreement with Vireo Growth Inc. (formerly Goodness Growth Holdings, Inc.)

 

Subsequent to year-end, the Company appointed Andrew Marchington as Chief Financial Officer and Josh Rosen as Chief Strategy Officer

 

Subsequent to year-end Nile, the Company’s affiliated dispensary located in West New York, New Jersey, opened in February 2025, with its grand opening event planned for Saturday, March 29

 

Subsequent to year-end, the Company closed a US$7.0M credit facility at ~9% interest

 

2024 Fourth Quarter Financial Highlights:

 

Revenue of $5.7M and adjusted EBITDA of $2.6M

 

Adjusted EBITDA margin of 46.9%

 

 

 

Management Commentary

 

“This was another productive year for Grown Rogue with growth in both revenue and aEBITDA showing the continued execution by our team in competitive markets against a backdrop of price compression that was most pronounced in the back half of the year. Our core markets of Oregon and Michigan performed well in 2024 with strong market share increases in both markets. Our sales in OR and MI grew 10% and 13%, respectively, while state sales in OR were flat and MI were up 8%, indicating continued strong demand for our flower and pre-roll products. Our state-level EBITDA margins in 2024 were affected by lower pricing, particularly in Oregon, but we remain relentlessly focused on offsetting this competitive environment with strong cost controls, operational efficiencies and yield improvements. We continue to see pricing pressure early in 2025, most significantly in Michigan and we’re optimistic that we’ll see this pressure subside as we move through the year. Fortunately, our strong execution and resulting margin profile makes us resilient.,” said Obie Strickler, CEO of Grown Rogue.

 

“I’m so proud of everyone on the Grown Rogue team for both maintaining the focus on continuous improvement in our existing operations and simultaneously delivering against an aggressive go-to-market timeline in New Jersey. Augmenting our team as we grow, while retaining and growing our core talent, is the linchpin of our success. I believe we’re doing a remarkable job of executing against the things we control. Our near-term focus remains on continuous operational improvements, construction of phase two at the New Jersey facility, the buildout of our facility in Illinois, and our ongoing measured pursuit of new markets. Our recently announced credit facility supports these growth initiatives on attractive terms by industry standards. We continue to believe that high-quality, low-cost cannabis cultivation, that delights consumers, is a protectable moat when done at the proper scale,” continued Mr. Strickler.

 

“I want to personally thank all our customers, the entire Grown Rogue team, and our supportive partners and shareholders for each doing their part to help Grown Rogue achieve our goal of becoming a nationally recognized craft flower company in the U.S. I look forward to providing future updates, most notably as we actively increase our penetration in the New Jersey market.”

 

Oregon Market Highlights ($USD Millions)

 

Oregon   FY 2024     FY 2023*     +/- %  
Revenue     12.1       11.0       +10 %
aEBITDA     3.6       4.4       -18 %
aEBITDA Margin %     30.0 %     40.1 %     -1010 bps  

 

 
* FY 2023 data is from November 2022 to October 2023

 

Michigan Market Highlights ($USD Millions)

 

Michigan   FY 2024     FY 2023*     +/- %  
Revenue     12.9       11.4       +13 %
aEBITDA     5.8       5.3       +8 %
aEBITDA Margin %     44.5 %     46.7 %     -220 bps  

 

 
* FY 2023 data is from November 2022 to October 2023

 

Michigan operations are through Golden Harvests, LLC.

 

2

 

Financial Statements and aEBITDA reconciliation

 

Consolidated Statements of Financial Position   December 31,
2024
    December 31,
2023
    October 31,
2023
 
    $     $     $  
ASSETS                        
Current assets                        
Cash and cash equivalents (Note 18)     4,682,221       6,804,579       8,858,247  
Accounts receivable (Note 18)     1,596,912       1,642,990       2,109,424  
Biological assets (Note 3)     1,554,622       1,723,342       1,566,822  
Inventory (Note 4)     4,769,776       5,021,290       4,494,257  
Prepaid expenses and other assets     864,009       420,336       392,787  
Notes receivable (Note 6.3)     7,189,635       -       -  
Total current assets     20,657,175       15,612,537       17,421,537  
Warrants asset (Note 13.2)     4,855,795       8,820,897       8,753,266  
Other Investments (Note 6.1 and 6.2)     1,810,363       -       -  
Notes receivable (Notes 6.3)     2,613,969       2,449,122       1,430,526  
Property and equipment (Note 8)     11,870,220       1,761,382       1,361,366  
Intangible assets and goodwill (Note 9)     1,257,668       725,668       725,668  
Deferred tax asset (Note 20)     250,620       246,294       470,358  
TOTAL ASSETS     43,315,810       29,615,900       30,162,721  
LIABILITIES                        
Current liabilities                        
Accounts payable and accrued liabilities     2,107,619       1,358,962       2,359,750  
Current portion of lease liabilities (Note 7)     736,453       925,976       824,271  
Current portion of long-term debt (Note 10)     227,679       780,358       1,285,604  
Current portion of convertible debentures (Note 11)     1,945,226       -       -  
Current portion of business acquisition consideration payable (Note 5)     536,881       360,000       360,000  
Derivative liability (Notes 11.1.1, 11.2 and 11.2.1)     12,504,175       7,471,519       7,808,500  
Income tax payable (Note 20)     1,907,177       873,388       366,056  
Total current liabilities     19,965,210       11,770,203       13,004,181  
Lease liabilities (Note 7)     4,475,490       1,972,082       2,094,412  
Long-term debt (Note 10)     1,001,681       82,346       102,913  
Business acquisition consideration payable (Note 5)     1,693,540       -       -  
Convertible debentures     -       2,459,924       2,412,762  
Other non-current liabilities (Note 20)     269,883       -       -  
TOTAL LIABILITIES     27,405,804       16,284,555       17,614,268  
EQUITY                        
Share capital (Note 12)     38,499,491       24,593,422       24,593,422  
Contributed surplus (Notes 13 and 14)     9,025,541       8,186,297       8,081,938  
Accumulated other comprehensive loss     (125,930 )     (108,069 )     (114,175 )
Accumulated deficit     (32,847,334 )     (20,353,629 )     (20,996,449 )
Equity attributable to shareholders     14,551,768       12,318,021       11,564,736  
Non-controlling interests (Note 23)     1,358,238       1,013,324       983,717  
TOTAL EQUITY     15,910,006       13,331,345       12,548,453  
TOTAL LIABILITIES AND EQUITY     43,315,810       29,615,900       30,162,721  

 

3

 

Consolidated Statements of Comprehensive Income (Loss)   Year ended
December 31,
2024
    Two months ended
December 31,
2023
    Year ended
October 31,
2023
 
    $     $     $  
Revenue                        
Product sales (Note 2.1.6.1)     25,029,634       3,542,037       22,424,169  
Service revenue (Note 2.1.6.2)     1,987,631       96,050       929,016  
Total revenue     27,017,265       3,638,087       23,353,185  
Cost of goods sold                        
Cost of finished cannabis inventory sold     (12,827,041 )     (1,404,323 )     (11,155,676 )
Costs of service revenue     (206,669 )     (89,210 )     (308,641 )
Gross profit, excluding fair value items     13,937,355       2,144,554       11,888,868  
Realized fair value loss amounts in inventory sold     (3,358,862 )     (460,647 )     (2,573,151 )
Unrealized fair value gain amounts on growth of biological assets     2,816,943       686,867       3,355,797  
Gross profit     13,441,636       2,370,774       12,671,514  
Expenses                        
Amortization of property and equipment     939,727       186,415       578,641  
General and administrative (Note 19)     10,075,360       1,437,353       6,465,877  
Share-based compensation     1,306,607       104,359       346,113  
Total expenses     12,321,694       1,728,127       7,390,631  
Income from operations     1,119,942       642,647       5,280,883  
Other income and (expense)                        
Interest expense     (379,161 )     (69,164 )     (370,616 )
Accretion expense     (2,042,556 )     (216,493 )     (1,026,732 )
Other income (expense)     1,938,713       49,678       441,487  
Gain on extinguishment on note receivable     156,165       -       -  
Unrealized gain (loss) on derivative liability     (12,768,905 )     336,981       (4,563,498 )
Unrealized gain on warrants asset     3,094,413       400,016       129,113  
Loss on equity investment in associate     (169,637 )     -       -  
Gain (loss) on disposal of property and equipment     50,057       (87,699 )     (182,025 )
Total other income (expense), net     (10,120,911 )     413,319       (5,572,271 )
Income (loss) before taxes     (9,000,969 )     1,055,966       (291,388 )
Income tax (Note 20)     (1,695,825 )     (383,539 )     (370,932 )
Net income (loss)     (10,696,794 )     672,427       (662,320 )
Other comprehensive income (items that may be subsequently reclassified to profit & loss)                        
Currency translation gain (loss)     (17,861 )     6,106       (4,562 )
Total comprehensive income (loss)     (10,714,655 )     678,533       (666,882 )
Gain (loss) per share attributable to owners of the parent – basic     (0.05 )     0.00       (0.00 )
Weighted average shares outstanding – basic     209,441,725       182,005,886       172,708,792  
Gain (loss) per share attributable to owners of the parent – diluted     0.01       0.00       0.00  
Weighted average shares outstanding – diluted     237,428,458       214,046,728       172,708,792  
Net income (loss) for the period attributable to:                        
Non-controlling interest     606,848       29,607       (129,279 )
Shareholders     (11,303,642 )     642,820       (533,041 )
Net income (loss)     (10,696,794 )     672,427       (662,320 )
Comprehensive income (loss) for the period attributable to:                        
Non-controlling interest     606,848       29,607       (129,279 )
Shareholders     (11,321,503 )     648,926       (537,603 )
Total comprehensive income (loss)     (10,714,655 )     678,533       (666,882 )

 

4

 

Consolidated Statements of Cash Flows   Year ended
December 31,
2024
    Two months ended
December 31,
2023
    Year ended
October 31,
2023
 
    $     $     $  
Operating activities                        
Net income (loss)     (10,696,794 )     672,427       (662,320 )
Adjustments for non-cash items in net income (loss):                        
Depreciation of property and equipment     939,727       186,415       578,641  
Amortization of property and equipment included in costs of inventory sold     1,980,597       209,985       1,757,672  
Unrealized fair value gain amounts on growth of biological assets     (2,816,943 )     (686,867 )     (3,355,797 )
Realized fair value loss amounts in inventory sold     3,358,862       460,647       2,573,151  
Deferred income taxes     (4,326 )     224,064       (470,358 )
Share-based compensation     1,306,607       104,359       344,593  
Accretion expense     2,042,556       216,493       1,026,732  
Loss on equity investment in associate     169,637       -       -  
Gain on extinguishment on note receivable     (156,165 )     -       -  
(Gain) Loss on disposal of property and equipment     (50,057 )     87,699       182,025  
Unrealized (gain) loss on fair value of derivative liability     12,768,905       (336,981 )     4,563,498  
Unrealized gain on warrants asset     (3,094,414 )     (400,016 )     (129,113 )
Currency translation gain (loss)     (17,861 )     6,106       (2,210 )
      5,730,331       744,331       6,406,514  
Changes in non-cash working capital (Note 15)     1,394,111       (513,222 )     (677,163 )
Net cash provided by operating activities     7,124,442       231,109       5,729,351  
                         
Investing activities                        
Purchase of property and equipment and intangibles     (1,739,014 )     (126,690 )     (1,456,782 )
Acquisition of Canopy Management and Golden Harvests     (801,436 )     -       -  
Dividend issued from Golden Harvests, LLC to minority owner     (530,000 )     -       -  
Cash advances and loans made to other parties     (7,898,136 )     (1,018,596 )     (1,430,526 )
Repayment of notes receivable principal and interest     484,160                  
Equity investment in ABCO Garden State LLC     (1,980,000 )     -       -  
Repayment of bridge note     266,417       -       -  
Net cash used in investing activities     (12,198,009 )     (1,145,286 )     (2,887,308 )
                         
Financing activities                        
Proceeds from convertible debentures     -       -       8,000,000  
Proceeds from exercise of warrants     4,657,460       -       -  
Proceeds from exercise of stock options     359,958       -       -  
Proceeds from sales of membership units     787,500       -       -  
Payment of debt and equity issuance costs     (126,914 )     -       -  
Repayment of long-term debt     (1,230,093 )     (568,166 )     (1,631,830 )
Repayment of convertible debentures     (521,953 )     (126,978 )     (261,006 )
Payments of lease principal     (974,749 )     (444,347 )     (1,673,344 )
Net cash provided by (used in) financing activities     2,951,209       (1,139,491 )     4,433,820  
                         
Change in cash and cash equivalents     (2,122,358 )     (2,053,668 )     7,275,863  
Cash and cash equivalents, beginning     6,804,579       8,858,247       1,582,384  
Cash and cash equivalents, ending     4,682,221       6,804,579       8,858,247  

 

5

 

Adjusted EBITDA Reconciliation   Year ended
December 31
2024
    Two months ended December 31
2023
    Year ended
October 31
2023
 
    ($)     ($)     ($)  
Net income (loss), as reported     (10,696,794 )     672,427       (662,320 )
Add back realized fair value amounts included in inventory sold     3,358,862       460,647       2,573,151  
Deduct unrealized fair value gain on growth of biological assets     (2,816,943 )     (686,867 )     (3,355,797 )
Add back amortization of property and equipment included in cost of sales     1,980,598       209,985       1,757,672  
      (8,174,277 )     656,192       312,706  
Add back interest and interest accretion expense, as reported     2,421,717       285,657       1,397,348  
Add back amortization of property and equipment, as reported     939,727       186,415       578,641  
Add back share-based compensation     1,306,607       104,359       346,113  
Deduct unrealized gain/add back unrealized loss on derivative liability, as reported     12,768,905       (336,981 )     4,563,498  
Deduct gain / add back loss on disposal of property plant and equipment     (50,057 )     87,699       -  
Deduct unrealized gain on warrants asset, as reported     (3,094,413 )     (400,016 )     (129,113 )
Deduct gain on extinguishment on note receivable     (156,165 )                
Add back income tax expense, as reported     1,695,825       383,539       370,932  
EBITDA     7,657,869       966,864       7,440,125  
Compliance costs1     -       -       83,747  
One time compensation payments     264,336       -       -  
Additional compliance costs associated with year end change     79,091       -       -  
Costs associated with acquisition of Golden Harvests 2     603,000       20,000       110,000  
New production location startup costs 3     887,897       -       -  
Non recurring legal and transaction costs     187,342       -       -  
Adjusted EBITDA     9,679,535       986,864       7,633,872  

 

 
1 Costs for professional services pertaining to prior periods as a result of efforts to bring the Company’s disclosures current with the Securities & Exchange Commission. The Company’s required disclosures were brought current, and over-the-counter trading resumed in the United States.
2 Costs associated with the Company’s acquisition of the Michigan assets.
3 During the year ended December 31, 2024, we incurred 887,897 in pre-opening labor costs associated with the investment in New Jersey.

 

6

 

Segmented Adjusted EBITDA

 

    Oregon     Michigan     Services     Corporate     Consolidated  
Revenue     12,093,606       12,936,028       1,258,131       729,500       27,017,265  
Costs of revenue     (7,125,199 )     (5,701,841 )     (206,670 )     -       (13,033,710 )
Gross profit     4,968,407       7,234,187       1,005,261       729,500       13,983,555  
Net fair value (“FV”) adjustments     210,468       (752,387 )     -       -       (541,919 )
Gross profit     5,178,875       6,481,800       1,005,261       729,500       13,441,636  
Operating expenses:                                        
General and administration     2,603,427       2,762,657       -       4,709,276       10,075,360  
Depreciation and amortization     115,851       641,120       -       182,756       939,727  
Share based compensation     -       -       -       1,306,607       1,306,607  
Other income and expense:                                        
Interest and accretion     (241,572 )     (73,361 )     -       (2,106,784 )     (2,421,717 )
Loss on disposal or property and equipment     5,280       44,777       -       -       50,057  
Gain on extinguishment on note receivable     -       -       -       156,165       156,165  
Unrealized (loss) gain on derivative liability     -       -       -       (12,768,905 )     (12,768,905 )
Unrealized (loss) gain on warrants asset     -       -       -       3,094,413       3,094,413  
Other income and expense     2,878       238,848       800,000       896,987       1,938,713  
Net income (loss) before tax     2,226,183       3,288,287       1,851,461       (16,366,900 )     (9,000,969 )
Tax     -       -       -       1,695,825       1,695,825  
Net income (loss) after tax     2,226,183       3,288,287       1,851,461       (18,062,725 )     (10,696,794 )
Net FV adjustments     (210,468 )     752,387       -       -       541,919  
Amortization of property and equipment included in cost of sales     1,254,370       726,228       -       -       1,980,598  
Amortization of property and equipment     115,851       641,120       -       182,756       939,727  
Share-based compensation     -       -       -       1,306,607       1,306,607  
Gain on extinguishment on note receivable     -       -       -       (156,165 )     (156,165 )
Unrealized derivative liability     -       -       -       12,768,905       12,768,905  
Loss on disposal of property plant and equipment     (5,280 )     (44,777 )     -       -       (50,057 )
Unrealized warrants asset     -       -       -       (3,094,413 )     (3,094,413 )
Interest and accretion     241,572       73,361       -       2,106,784       2,421,717  
Income tax     -       -       -       1,695,825       1,695,825  
EBITDA before one-time adjustments     3,622,228       5,436,606       1,851,461       (3,252,426 )     7,657,869  
Add back to EBITDA:                                        
One time compensation payments     -       -       -       264,336       264,336  
Additional compliance costs     -       -       -       79,091       79,091  
Eliminated management fees     -       -       -       -       46,200  
Costs associated with acquisition of Golden Harvests     -       323,000       -       280,000       603,000  
New production location startup costs     -       -       -       887,897       887,897  
Non recurring legal and transaction costs     -       -       -       187,342       187,342  
Adjusted EBITDA     3,622,228       5,759,606       1,851,461       (1,553,760 )     9,679,535  

 

7

 

NOTES:

 

1. The Company’s “aEBITDA,” or “Adjusted EBITDA,” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines “EBITDA” as the Company’s net income or loss for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities, the effects of fair-value accounting for biological assets and inventory, as well as other non-cash items and items not representative of operational performance as reported in net income (loss). Adjusted EBITDA is defined as EBITDA adjusted for the impact of various significant or unusual transactions. The Company believes that this is a useful metric to evaluate its operating performance.

 

NON-IFRS FINANCIAL MEASURES

 

EBITDA and aEBITDA are non-IFRS measures and do not have standardized definitions under IFRS. The Company has also provided unaudited pro-forma financial information, which assumes that closed and pending mergers and acquisitions in 2021 are included in the Company’s financial results as of the beginning of the quarterly and annual periods in 2021. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. Accordingly, the following information provides reconciliations of the supplemental non-IFRS financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.

 

About Grown Rogue

 

Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a craft cannabis company operating in Oregon, Michigan, New Jersey and Illinois, focused on delighting customers with premium flower and flower-derived products at fair prices. The Company’s roots are in Southern Oregon, where it has proven its capabilities in the highly competitive and discerning Oregon market. The Company’s passion for quality product and value, combined with a disciplined approach to growth, prioritizes profitability and return on capital without sacrificing quality. The Company’s strategy is to pursue capital efficient methods to expand into new markets, bringing craft-quality product at fair prices to more consumers. The Company also continues to make modest investments to improve outdoor craft cultivation capabilities in preparation for eventual interstate commerce. For more information, visit www.grownrogue.com.

 

8

 

FORWARD-LOOKING STATEMENTS

 

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Company’s public disclosure documents filed on Sedar.

 

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

 

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States through its indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are disclosed in the Company’s Listing Statement filed on its issuer profile on SEDAR+ at www.sedarplus.ca. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

 

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

 

9

 

For further information on Grown Rogue, please visit www.grownrogue.com or contact:

 

Obie Strickler

Chief Executive Officer

obie@grownrogue.com

 

Jakob Iotte

Vice President of Investor Relations

jakeiotte@grownrogue.com

 

(458) 226-2662

 

10